Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 13/20 | 0.79 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.56 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.55 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.55 |
| ▸ | NAMPT | P43490 | 3/20 | 0.55 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.52 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.52 |
| ▸ | VCP | P55072 | 1/20 | 0.52 |
| ▸ | CNR1 | P21554 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3606835 | 0.94 | KDR (0.79) | KDRROCK1LIMK1LIMK2NAMPT | |
| SCHEMBL3651635 | 0.89 | KDR (1.00) | KDRROCK1NAMPT | |
| SCHEMBL3605321 | 0.86 | KDR (0.58) | KDRROCK1LIMK1LIMK2NAMPT | |
| SCHEMBL6332623 | 0.84 | KDR (0.79) | KDRROCK1LIMK1NAMPTCNR1 | |
| SCHEMBL20380021 | 0.84 | KDR (0.79) | KDRROCK1NAMPT | |
| SCHEMBL20379918 | 0.84 | KDR (0.72) | KDRROCK1NAMPTCNR1 | |
| SCHEMBL3602543 | 0.83 | VCP (0.58) | KDRLIMK1LIMK2NAMPTVCP | |
| SCHEMBL6330404 | 0.83 | KDR (1.00) | KDRROCK1LIMK1NAMPT | |
| SCHEMBL6336620 | 0.82 | KDR (0.74) | KDRROCK1NAMPT | |
| SCHEMBL3602411 | 0.82 | KDR (0.53) | KDRROCK1LIMK1LIMK2NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050228031-A1 | Tyrosine kinase inhibitors | BILODEAU MARK T | 2005-10-13 | — | — | US | claimed |
| US-20050228031-A1 | Tyrosine kinase inhibitors | BILODEAU MARK T | 2005-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050228031-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | KDR 5/4885ROCK1 152/4885LIMK1 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.